Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Bonanno L, Dómine M, Poole L, Bolanos A, Rukazenkov Y, Wu YL.
Tsuboi M, et al. Among authors: goldman jw.
Target Oncol. 2024 Mar 11. doi: 10.1007/s11523-024-01034-3. Online ahead of print.
Target Oncol. 2024.
PMID: 38466534